219 related articles for article (PubMed ID: 19227770)
1. [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
Ivanov S; Batashki I
Akush Ginekol (Sofiia); 2008; 47(5):9-11. PubMed ID: 19227770
[TBL] [Abstract][Full Text] [Related]
2. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
3. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.
Soliman PT; Slomovitz BM; Broaddus RR; Sun CC; Oh JC; Eifel PJ; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Aug; 94(2):456-62. PubMed ID: 15297188
[TBL] [Abstract][Full Text] [Related]
4. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.
Zwart J; Geisler JP; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(3):225-8. PubMed ID: 9641218
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
Kieback DG; Press MF; McCamant SK; Atkinson EN; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):189-94. PubMed ID: 7789706
[TBL] [Abstract][Full Text] [Related]
6. Carcinosarcoma of the ovary: 19 years of prospective data from a single center.
Brown E; Stewart M; Rye T; Al-Nafussi A; Williams AR; Bradburn M; Smyth J; Gabra H
Cancer; 2004 May; 100(10):2148-53. PubMed ID: 15139057
[TBL] [Abstract][Full Text] [Related]
7. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
8. Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up.
Bouchard-Fortier G; Panzarella T; Rosen B; Chapman W; Gien LT
J Obstet Gynaecol Can; 2017 Jan; 39(1):34-41. PubMed ID: 28062021
[TBL] [Abstract][Full Text] [Related]
9. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
[TBL] [Abstract][Full Text] [Related]
12. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
14. Management of borderline ovarian tumors.
Tîrnovanu MC; Amancei S; Dumitrescu A; Onofriescu M; Dumitraşcu I
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1069-75. PubMed ID: 23700890
[TBL] [Abstract][Full Text] [Related]
15. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
Davis M; Rauh-Hain JA; Andrade C; Boruta DM; Schorge JO; Horowitz NS; May T; del Carmen MG
Gynecol Oncol; 2014 Mar; 132(3):760-6. PubMed ID: 24440832
[TBL] [Abstract][Full Text] [Related]
17. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
Roger N; Zafrani Y; Uzan C; Gouy S; Rey A; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
Ann Surg Oncol; 2008 Jan; 15(1):333-8. PubMed ID: 17943386
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
Sherman ME; Sturgeon S; Brinton LA; Potischman N; Kurman RJ; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD
Mod Pathol; 1997 Oct; 10(10):963-8. PubMed ID: 9346174
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
Chen F; Shen K; Lang JH; Huang HF; Wu M
Zhonghua Yi Xue Za Zhi; 2005 May; 85(18):1257-60. PubMed ID: 16029611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
